Evommune (EVMN) Current Assets (2024 - 2026)

Evommune (EVMN) posted quarterly Current Assets of $215.9 million for Q1 2026, up 40.64% quarter-over-quarter from $153.5 million in Q4 2025.

Evommune (EVMN) Current Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Current Assets for 3 consecutive years, with $215.9 million the latest figure, recorded in Q1 2026.

In Q1 2026, Current Assets changed N/A year-over-year to $215.9 million; the TTM figure through Mar 2026 stood at $215.9 million (changed N/A YoY), while the FY2025 annual figure was $153.5 million, up 107.44% from the prior year.
Current Assets climbed to $215.9 million in Q1 2026 per EVMN's latest filing, from $153.5 million in the prior quarter.
Across five years, Current Assets topped out at $215.9 million in Q1 2026 and bottomed at $74.0 million in Q4 2024.
Historically, Current Assets has averaged $131.3 million across 3 years, with a median of $117.7 million in 2025.
On a YoY basis, Current Assets climbed as much as 107.44% in 2025 and fell as far as 107.44% in 2025.
Evommune's Current Assets stood at $74.0 million in 2024, then soared by 107.44% to $153.5 million in 2025, then jumped by 40.64% to $215.9 million in 2026.
Business Quant data shows EVMN's Current Assets at $215.9 million in Q1 2026, $153.5 million in Q4 2025, and $81.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	12.54 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	18.45 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	8.07 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	4.03 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	7.22 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	11.83 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	1.76 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	4.62 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.63 Bn
10	Evommune	531.53 Mn	330.73 Mn	-	204.25 Mn

Download Data